FDA Approves Talazoparib in BRCA+ Breast Cancer FDA Approves Talazoparib in BRCA+ Breast Cancer

Compared with standard chemotherapy, the PARP inhibitor extended progression-free survival for patients with advanced BCRA-positive breast cancer.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news